You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Litigation Details for Cirba Inc. (d/b/a Densify) v. VMware, Inc. (D. Del. 2019)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Cirba Inc. (d/b/a Densify) v. VMware, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Litigation Summary and Analysis for Cirba Inc. (d/b/a Densify) v. VMware, Inc. | 1:19-cv-00742

Last updated: August 11, 2025


Introduction

The legal dispute between Cirba Inc. (operating as Densify) and VMware, Inc. centers on allegations of patent infringement concerning virtualization management technologies. Densify, a provider of cloud optimization solutions, initiated action against VMware, a global leader in virtualization software, claiming infringement of patented innovations related to resource optimization and workload management. This detailed analysis synthesizes the procedural history, claims, defenses, and strategic implications to inform industry stakeholders and legal professionals.


Case Overview

Parties Involved:

  • Plaintiff: Cirba Inc., doing business as Densify
  • Defendant: VMware, Inc.

Jurisdiction:
United States District Court for the District of Delaware, docket number 1:19-cv-00742.

Filing Date:
March 12, 2019.

Nature of Litigation:
Patent infringement concerning technology designed to enhance virtualization and cloud resource allocation.


Patent Allegations and Key Claims

Densify’s complaint asserts that VMware infringes upon multiple patents related to dynamic workload placement, resource utilization optimization, and automated provisioning—classifying these as core innovations for efficient virtualization and cloud infrastructure management.

The patents in question—filed between 2012 and 2016—cover innovations in:

  • Smart resource allocation algorithms (e.g., US Patent 9,555,783),
  • Automated workload balancing techniques, and
  • Intelligent provisioning systems.

Densify alleges that VMware’s vSphere and vRealize suite incorporate these patented methods without licensing, thus infringing on Densify’s intellectual property rights.


Procedural Developments

Initial Complaint (2019):
Densify filed the complaint alleging direct patent infringement, seeking monetary damages, injunctive relief, and attorneys’ fees.

Discovery Phase (2020-2021):
Both parties engaged in document exchanges, depositions, and technical analyses. VMware contested the validity of the patents, asserting prior art invalidity and non-infringement.

Summary Judgment Motions (2022):
VMware moved for summary judgment, primarily challenging patent validity and infringement, leading to a court analysis of patent scope and prior art references.

Settlement and Mediation (2023):
The case was in ongoing litigation, with settlement discussions occurring, but no formal resolution reported as of the latest court filings.


Legal and Strategic Analysis

Patent Validity Concerns:
VMware’s invalidity arguments hinge on prior art references predating Densify’s patents, including academic publications and earlier virtualization technologies. Patent office re-examinations, however, initially upheld the patent claims, strengthening Densify’s position.

Infringement Analysis:
The patents’ claims are specific to algorithmic processes executed within a virtualization environment. VMware’s products allegedly implement similar functionalities, leading to infringement allegations supported by technical expert testimony.

Implications for the Industry:
This case exemplifies the rising importance of patent protections in cloud infrastructure innovation, especially as virtualization technology becomes more sophisticated. Patent litigations like this can influence licensing strategies and product development pipelines.


Impact and Market Implications

For Densify:
Success in court could establish strong patent rights, potentially leading to licensing agreements, settlement payments, or injunctive relief restricting VMware’s infringing products.

For VMware:
The case underscores the need for continuous innovation and patent clearance. VMware’s defense strategies, including patent validity challenges or design-around approaches, are pivotal in mitigating risks.

Broader Industry Signal:
This litigation signals heightened vigilance over intellectual property rights in virtualization technology, urging companies to conduct thorough patent landscape analyses and strengthen their patent portfolios.


Conclusion

The litigation between Cirba Inc. (Densify) and VMware exemplifies the intersection of technological innovation and intellectual property rights in the cloud and virtualization domain. Although ongoing, the case underscores critical strategic considerations for vendors and providers in safeguarding their innovations through patents. The outcome may redefine licensing frameworks and influence patent enforcement policies in cloud infrastructure technology.


Key Takeaways

  • Patent infringement lawsuits in cloud technology are increasingly prevalent, underscoring the value of comprehensive IP strategies.
  • Validity defenses grounded in prior art remain central in patent litigation, often determining case outcomes.
  • Technical specificity in patent claims demands detailed infringement analyses backed by expert testimony.
  • Litigation outcomes can significantly influence market competition and licensing dynamics in virtualization technology.
  • Continuous patent landscape monitoring is essential for innovation protection and risk mitigation in rapidly evolving tech sectors.

Frequently Asked Questions

Q1: What are the main patents involved in the Densify v. VMware case?
A1: The case centers on patents related to dynamic workload placement algorithms and resource management systems, notably US Patent 9,555,783, covering intelligent resource allocation techniques.

Q2: Has the case been settled or dismissed?
A2: As of the latest filings, the case remains active with ongoing proceedings; no settlement has been publicly announced.

Q3: How does patent validity impact this litigation?
A3: VMware contests the patents' validity via prior art references, a common defense in patent infringement cases that can render patents unenforceable if successful.

Q4: What are potential outcomes for VMware if infringement is proven?
A4: Possible outcomes include monetary damages, injunctions against infringing products, or licensing agreements favoring Densify.

Q5: How can companies avoid patent infringement in virtualization innovation?
A5: By conducting thorough patent landscape analyses, designing around existing patents, and pursuing strategic patent filings to cover their innovations.


References
[1] Court docket for Cirba Inc. v. VMware, Inc., 1:19-cv-00742, U.S. District Court for the District of Delaware.

[2] Patent documents and filings publicly accessible via USPTO Patent Full-Text and Image Database.

[3] Industry analyses and patent law commentary on virtualization technology patents.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.